Form 4: Macrogenics Sr VP Exercises RSUs, Sells for Tax

Macrogenics Senior Vice President of Technical Operations, Thomas Spitznagel, exercised restricted stock units and sold a portion of the resulting common stock to cover tax obligations.

Summary

• Thomas Spitznagel, Senior Vice President of Technical Operations at Macrogenics Inc. (MGNX), reported transactions on February 7 and February 8, 2026.
• On February 7, 2026, Spitznagel acquired 6,001 shares of common stock through the conversion of restricted stock units (RSUs).
• Immediately following the acquisition on February 7, 2026, 2,485 shares were disposed of at $1.81 per share to cover tax withholding obligations.
• On February 8, 2026, an additional 8,999 shares of common stock were acquired from RSU conversions.
• Subsequently, on February 8, 2026, 3,186 shares were disposed of at $1.81 per share for tax withholding purposes.
• The RSUs convert into common stock on a one-for-one basis with an exercise price of $0.
• The 6,001 RSUs converted on February 7, 2026, were part of a 18,000 RSU grant from February 7, 2025, vesting in three equal installments.
• The 8,999 RSUs converted on February 8, 2026, were part of a 27,000 RSU grant from February 8, 2024, also vesting in three equal installments.
• Following these transactions, Spitznagel directly beneficially owns 30,731 shares of common stock and 20,999 derivative securities (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents routine insider transactions related to executive compensation and tax obligations, rather than discretionary buying or selling.

Positives

• An insider (Sr VP) is acquiring common stock through RSU conversions, indicating continued equity ownership and alignment with shareholder interests.
• The RSU conversions represent a scheduled vesting event, which is a standard component of executive compensation.

Negatives

• A portion of the acquired shares was immediately sold to cover tax obligations, which, while common practice, reduces the net increase in direct ownership.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insiders, reflecting standard executive compensation practices involving equity awards. These transactions, while not indicative of discretionary buying or selling, provide transparency into insider holdings and vesting schedules within the biotechnology sector.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures across all industries for reporting insider transactions.
• The RSU vesting and subsequent sale for tax purposes are common practices for executives receiving equity compensation in publicly traded companies, including those in the biotech and pharmaceutical sectors like Macrogenics.
• There are no specific comparable companies, projects, or results mentioned in this filing to assess against.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive equity ownership and compensation, but the transactions themselves are routine and unlikely to have a direct material impact on company operations or strategy.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Remaining restricted stock units from the February 7, 2025 grant will vest in two more equal installments.
• Remaining restricted stock units from the February 8, 2024 grant will vest in one more equal installment.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting of restricted stock units and subsequent sales for tax purposes. It does not provide new material information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing company fundamentals and market outlook.

Keywords

Macrogenics, MGNX, Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Executive Compensation, Stock Sale, Tax Withholding, Thomas Spitznagel